Darrin R. Uecker is our Chief Technology Officer and a member of our Board of Directors. He entered into an employment agreement with the Company on September 8, 2015, when he joined the Company as our President and Chief Executive Officer. The agreement was amended on October 5, 2016, in advance of the Company's initial public offering of shares. It was again amended on September 20, 2022, when the Board appointed him as our Chief Technology Officer, so that he could focus his efforts on new product development in cardiology. The agreement has been amended since September 2022 to change certain provisions, such as his base salary and bonus target. His employment agreement, as amended, has no specific term and constitutes at-will employment. His current annual base salary is $525,000. Presently, he is eligible for an annual target bonus equal to 70% of his annual base salary, subject to achievement of performance objectives. He is also eligible to participate in employee benefit plans maintained from time to time by us of general applicability to other senior executives. Prior to their expiry on September 8, 2025, he exercised the options he received when he joined the Company to purchase up to 281,534 shares of common stock at $4.00 per share. If we terminate his employment other than for cause, death, or disability or if he resigns for good reason, as defined in his employment agreement, then, subject to his execution of a release of claims in our favor and his compliance with certain restrictive covenants set forth in his employment agreement, he is entitled to receive continuing payments of his then-current base salary for a period of three months following his termination of employment (or for a period of twelve months if the termination occurs within twelve months of a Change of Control), less applicable withholdings, accelerated vesting as to that portion of his then outstanding and unvested options that would have vested had he remained an employee for twelve months following his termination date, and reimbursement of premiums to maintain group health insurance continuation benefits pursuant to COBRA for him and his respective dependents until the earlier of him or his eligible dependents becoming covered under similar plans, or the date upon which he ceases to be eligible for coverage under COBRA. He has also entered into our standard inventions assignment, confidentiality and non-competition agreement and our standard indemnification agreement for officers and directors.